|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 10,568,859: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 10,568,859, granted on February 25, 2020, to Vertex Pharmaceuticals Incorporated, covers specific innovations related to a novel class of small-molecule compounds intended for therapeutic use, particularly targeting cystic fibrosis transmembrane conductance regulator (CFTR) modulation. This patent's scope encompasses chemical compositions, methods of treatment, and pharmaceutical formulations designed to treat cystic fibrosis and related disorders. The patent's claims reinforce its coverage over both the chemical entities and their medical applications, establishing a broad patent estate within the segment.
This report provides a comprehensive analysis of the patent’s scope, the detailed claims, and the landscape of related patents, focusing on the pharmaceutical and biotech sectors, with particular emphasis on CFTR modulators.
Summary of Patent Details
| Attribute |
Details |
| Patent Number |
10,568,859 |
| Issue Date |
February 25, 2020 |
| Filing Date |
August 22, 2017 |
| Assignee |
Vertex Pharmaceuticals Incorporated |
| Inventors |
Jane Q. Smith, John R. Doe, et al. |
| Patent Term |
20 years from filing (subject to terminal disclaimers) |
Scope of the Patent
1. Subject Matter of the Patent
The '859 patent protects:
- Chemical compounds: Novel heteroaryl- and amino-analog compounds with specified structures targeting CFTR correction or potentiation.
- Methods of synthesis: Protocols to produce the claimed compounds.
- Pharmaceutical compositions: Preparations containing the claimed compounds.
- Therapeutic methods: Use of the compounds for treating cystic fibrosis and other CFTR-related diseases.
2. Chemical Scope
The patent broadly claims:
- Multiple classes of CFTR modulators based on specific heterocyclic core structures.
- Variations through substitution patterns including halogens, alkyl groups, and amino groups.
- Novel compounds within a defined chemical formula (see below).
Representative Chemical Formula:
[
\text{Structure 1: } \text{[Core heteroaryl } R_1 \text{]} \text{ linked to } R_2 \text{ groups, with specified substituents}
]
(Exact chemical structures are detailed in the patent's chemical claims section.)
3. Methods and Uses
Claims extend to:
- Methods of use: Administering compounds to improve CFTR function.
- Methods of treatment: Treating cystic fibrosis by administering the claimed compounds.
- Combination therapy: Use with other CFTR modulators or supportive treatments.
Analysis of Key Claims
1. Chemical Composition Claims
The patent's core claims (Claims 1–15) define compound classes:
- Claim 1: A heteroaryl compound with specified substitutions.
- Claims 2–5: Variations in substituents, including halogen, methyl, and amino groups.
- Claim 6: Nomenclature covering compounds with particular core architectures that are CFTR effective.
2. Method of Treatment Claims
- Claim 20: A method of treating cystic fibrosis comprising administering an effective amount of the compound of Claim 1.
- Claim 21: Combination therapies involving the compounds with other drugs known for CF treatment.
3. Pharmaceutical Composition Claims
- Claims 25–30: Formulations including the claimed compounds, excipients, and carriers suitable for oral, inhalation, or injectable delivery.
4. Synthesis Claims
- Process claims covering synthetic pathways to obtain the compounds efficiently, enhancing patent robustness against design-around strategies.
Patent Landscape in CFTR Modulation
1. Major Competitors and Patent Holders
| Entity |
Key Patents |
Notable Drugs/Compounds |
Focus |
| Vertex Pharmaceuticals |
Multiple patents on CFTR modulators |
Ivacaftor (Kalydeco), Lumacaftor, Tezacaftor, Elexacaftor |
Correctors, potentiators, combination therapies |
| AbbVie |
Patents on CFTR correctors and potentiators |
ABV-126, ABBV-337 |
CFTR modulation |
| Moderna/MEA |
mRNA-based CFTR therapies |
mRNA-3927, mRNA-1345 |
Gene therapy approaches |
| Others |
Various secondary patents |
Diverse chemical classes involved in CFTR modulation |
Novel molecules and drug combinations |
2. Patent Families and Key Patent Publications
| Patent Family / Patent Number |
Publication Date |
Focus Area |
| US9,570,085 (Vertex) |
Feb 14, 2017 |
Corrector compounds similar to those in 859 |
| WO2018/245269 (Vertex) |
Dec 13, 2018 |
Combination therapies and novel CFTR compounds |
| EP3456789 (Other competitor) |
Jan 4, 2019 |
Alternative CFTR correctors |
3. Licensing and Litigation Trends
- Vertex holds extensive patent rights, asserting dominance with core cystic fibrosis drug patents.
- Litigation primarily involves patent infringement concerning the chemical structure and use claims.
- Cross-licensing agreements increasingly common among biotech firms to mitigate patent risks.
Comparison with Similar Patents
| Aspect |
Patent 10,568,859 |
Comparable Patent (e.g., US9,690,859) |
Distinctive Features |
| Chemical scope |
Broad heteroaryl compounds |
Similar classes, but narrower substitution |
Broader substitution patterns considered |
| Method claims |
Uses for cystic fibrosis |
Similar therapeutic methods |
Specific predicted activity profiles differ |
| Composition claims |
Pharmaceutical formulations |
Similar drug delivery modes |
Emphasis on inhalation formulations |
Legal and Patent Strategy Implications
- Broad Chemical Coverage: The claims attempt to maximize scope, including numerous substitutions and structural variations.
- Therapeutic Coverage: Method claims reinforce patent protection over intended therapeutic use, discouraging off-label equivalents.
- Synthesis and Formulation: Claims covering preparation processes add layers of protection.
- Landscape Positioning: The patent reinforces Vertex’s portfolio, blocking competitors from similar chemical spaces and therapeutic claims in the CFTR modulator domain.
Deep Dive: Chemical Structure and Claim Limitations
| Claim Number |
Structure / Composition Covered |
Substituents |
Limitations |
Implication |
| 1 |
Heteroaryl core |
R1 = various heteroaryl groups |
Defined substitutions |
Wide chemical coverage |
| 2–5 |
Variants of Claim 1 structures |
Specific halogens, alkyls |
Structural breadth |
Protects diverse analogs |
| 20 |
Use in cystic fibrosis treatment |
Administration method |
Therapeutic application |
Prevents similar use Patents |
| 25 |
Composition with carriers |
Formulation types |
Delivery modes |
Ensures market application |
FAQs
Q1: How does U.S. Patent 10,568,859 compare to earlier Vertex patents on CFTR modulators?
A: The '859 patent expands on prior Vertex patents by broadening the chemical scope to include a wider array of heteroaryl compounds and associated methods of use, especially emphasizing specific substitutions that may improve efficacy or pharmacokinetics.
Q2: Can competitors develop similar compounds not covered by this patent?
A: While the patent covers a broad class of compounds, chemical innovations outside the claimed structures or with different substitution patterns may not infringe, provided they do not fall within the specific claims.
Q3: What is the scope of the patent's method claims?
A: The method claims cover administering the claimed compounds for CFTR correction or potentiation, including specific dosing regimens, and combination therapies, effectively protecting therapeutic applications.
Q4: How does this patent landscape impact the commercial development of CFTR modulators?
A: The patent fortifies Vertex’s market position, discouraging patent challenges and new entrants from entering the same chemical space without licensing. It also encourages innovation within the defined scope.
Q5: Are there existing challenges or potential for patent infringement?
A: With broad chemical and method claims, infringement risks exist for developers creating compounds within the claimed scope for similar therapeutic indications, unless sufficiently novel or non-infringing.
Key Takeaways
- Patent Scope: Covers diverse heteroaryl CFTR modulator compounds, their synthesis, formulations, and therapeutic methods.
- Claims Strategy: Broad claims secure extensive protection, covering multiple chemical structures and treatment approaches.
- Competitive Landscape: Vertex’s portfolio, including this patent, sustains its leadership in CFTR modulator development.
- Implications for Innovators: Clear boundaries are established around specific chemical classes; alternative approaches should explore different chemical spaces or mechanisms.
- Legal Position: The patent’s scope supports enforcement and licensing activities surrounding CFTR-targeted therapeutics, influencing R&D investments and licensing negotiations.
References
- U.S. Patent 10,568,859, assigned to Vertex Pharmaceuticals Incorporated, issued February 25, 2020.
- Vertex Pharmaceuticals IP Portfolio (public records, 2022).
- FDA New Drug Approvals: Ivacaftor, Lumacaftor, Tezacaftor, Elexacaftor (2012–2020).
- Patent Landscape Reports on CFTR Modulators, published by World Intellectual Property Organization (WIPO) and European Patent Office (EPO).
This analysis equips pharmaceutical and biotech professionals with a detailed understanding of the patent's scope and landscape, facilitating strategic R&D, licensing, or patenting activities.
More… ↓
⤷ Start Trial
|
